当前位置: 首页 >> 检索结果
1182. Agonist that activates the µ-opioid receptor in acidified microenvironments inhibits colitis pain without side effects.
作者: Nestor Nivardo Jiménez-Vargas.;Yang Yu.;Dane D Jensen.;Diana Daeun Bok.;Matthew Wisdom.;Rocco Latorre.;Cintya Lopez.;Josue O Jaramillo-Polanco.;Claudius Degro.;Mabel Guzman-Rodriguez.;Quentin Tsang.;Zachary Snow.;Brian L Schmidt.;David E Reed.;Alan Edward Lomax.;Kara Gross Margolis.;Christoph Stein.;Nigel W Bunnett.;Stephen J Vanner.
来源: Gut. 2022年71卷4期695-704页
The effectiveness of µ-opioid receptor (MOPr) agonists for treatment of visceral pain is compromised by constipation, respiratory depression, sedation and addiction. We investigated whether a fentanyl analogue, (±)-N-(3-fluoro-1-phenethylpiperidine-4-yl)-N-phenyl propionamide (NFEPP), which preferentially activates MOPr in acidified diseased tissues, would inhibit pain in a preclinical model of inflammatory bowel disease (IBD) without side effects in healthy tissues.
1187. Radiology-guided percutaneous approach is superior to EUS for performing liver biopsies.
作者: Ji Young Bang.;Thomas J Ward.;Shady Guirguis.;Konrad Krall.;Francisco Contreras.;Nirag Jhala.;Udayakumar Navaneethan.;Robert H Hawes.;Shyam Varadarajulu.
来源: Gut. 2021年70卷12期2224-2226页 1188. Predicting endoscopic remission in Crohn's disease by the modified multiplier SES-CD (MM-SES-CD).
作者: Neeraj Narula.;Emily C L Wong.;Jean-Frederic Colombel.;William J Sandborn.;John Kenneth Marshall.;Marco Daperno.;Walter Reinisch.;Parambir S Dulai.
来源: Gut. 2022年71卷6期1078-1087页
The Simple Endoscopic Score for Crohn's disease (SES-CD) is the primary tool for measurement of mucosal inflammation in clinical trials but lacks prognostic potential. We set to develop and validate a modified multiplier of the SES-CD (MM-SES-CD), which takes into consideration each individual parameter's prognostic value for achieving endoscopic remission (ER) while on active therapy.
1190. Activation of the GPR35 pathway drives angiogenesis in the tumour microenvironment.
作者: Ester Pagano.;Joshua E Elias.;Georg Schneditz.;Svetlana Saveljeva.;Lorraine M Holland.;Francesca Borrelli.;Tom H Karlsen.;Arthur Kaser.;Nicole C Kaneider.
来源: Gut. 2022年71卷3期509-520页
Primary sclerosing cholangitis (PSC) is in 70% of cases associated with inflammatory bowel disease. The hypermorphic T108M variant of the orphan G protein-coupled receptor GPR35 increases risk for PSC and ulcerative colitis (UC), conditions strongly predisposing for inflammation-associated liver and colon cancer. Lack of GPR35 reduces tumour numbers in mouse models of spontaneous and colitis associated cancer. The tumour microenvironment substantially determines tumour growth, and tumour-associated macrophages are crucial for neovascularisation. We aim to understand the role of the GPR35 pathway in the tumour microenvironment of spontaneous and colitis-associated colon cancers.
1192. Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab.
作者: Nicholas A Kennedy.;James R Goodhand.;Claire Bewshea.;Rachel Nice.;Desmond Chee.;Simeng Lin.;Neil Chanchlani.;Jeffrey Butterworth.;Rachel Cooney.;Nicholas M Croft.;Ailsa L Hart.;Peter M Irving.;Klaartje B Kok.;Christopher A Lamb.;Jimmy K Limdi.;Jonathan Macdonald.;Dermot Pb McGovern.;Shameer J Mehta.;Charles D Murray.;Kamal V Patel.;Richard Cg Pollok.;Timothy Raine.;Richard K Russell.;Christian P Selinger.;Philip J Smith.;Jack Bowden.;Timothy J McDonald.;Charlie W Lees.;Shaji Sebastian.;Nicholas Powell.;Tariq Ahmad.; .
来源: Gut. 2021年70卷5期865-875页
Antitumour necrosis factor (anti-TNF) drugs impair protective immunity following pneumococcal, influenza and viral hepatitis vaccination and increase the risk of serious respiratory infections. We sought to determine whether infliximab-treated patients with IBD have attenuated serological responses to SARS-CoV-2 infections.
1195. Composition, diversity and potential utility of intervention-naïve pancreatic cancer intratumoral microbiome signature profiling via endoscopic ultrasound.
作者: Ferga C Gleeson.;Patricio Jeraldo.;Michael J Levy.;Stephen J Murphy.;Helena Mendes-Soares.;Giannoula Karagouga.;Alexa F Mccune.;Ana Garcia Garcia Deparedes.;Benjamin R Kipp.;Stephanie D Song.;Sahil Khanna.;Darrell S Pardi.;Nicholas Chia.
来源: Gut. 2022年71卷2期441-443页 1196. Long-term outcomes after endoscopic treatment for Barrett's neoplasia with radiofrequency ablation ± endoscopic resection: results from the national Dutch database in a 10-year period.
作者: Sanne van Munster.;Esther Nieuwenhuis.;Bas L A M Weusten.;Lorenza Alvarez Herrero.;Auke Bogte.;Alaa Alkhalaf.;B E Schenk.;Erik J Schoon.;Wouter Curvers.;Arjun D Koch.;Steffi Elisabeth Maria van de Ven.;Pieter Jan Floris de Jonge.;Tjon J Tang.;Wouter B Nagengast.;Frans T M Peters.;Jessie Westerhof.;Martin H M G Houben.;Jacques Jghm Bergman.;Roos E Pouw.; .
来源: Gut. 2022年71卷2期265-276页
Radiofrequency ablation (RFA)±endoscopic resection (ER) is the preferred treatment for early neoplasia in Barrett's oesophagus (BE). We aimed to report short-term and long-term outcomes for all 1384 patients treated in the Netherlands (NL) from 2008 to 2018, with uniform treatment and follow-up (FU) in a centralised setting.
1197. Risk factors for SARS-CoV-2 infection and course of COVID-19 disease in patients with IBD in the Veterans Affair Healthcare System.
作者: Nabeel Khan.;Nadim Mahmud.;Chinmay Trivedi.;Walter Reinisch.;James D Lewis.
来源: Gut. 2021年70卷9期1657-1664页
Our aim was to explore the risk of infection with all classes of inflammatory bowel disease (IBD) medications and the impact of these medications on the disease course in a nationwide cohort of patients with IBD.
1198. Gastric per-oral endoscopic myotomy (G-POEM) for refractory gastroparesis: results from an international prospective trial.
作者: Kia Vosoughi.;Yervant Ichkhanian.;Petros Benias.;Larry Miller.;A Aziz Aadam.;Joseph R Triggs.;Ryan Law.;William Hasler.;Nicole Bowers.;Dalton Chaves.;Alberto M Ponte-Neto.;Peter Draganov.;Dennis Yang.;Maan El Halabi.;Omid Sanaei.;Olaya Isabella Brewer Gutierrez.;Robert Stephen Bulat.;John Pandolfino.;Mouen Khashab.
来源: Gut. 2022年71卷1期25-33页
Although gastric per-oral endoscopic myotomy (G-POEM) is considered a promising technique for the management of refractory gastroparesis, high-quality evidence is limited. We prospectively investigated the efficacy and safety of G-POEM in unselected patients with refractory gastroparesis.
1199. Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis.
作者: Victor Sapena.;Marco Enea.;Ferran Torres.;Ciro Celsa.;Jose Rios.;Giacomo Emanuele Maria Rizzo.;Pierre Nahon.;Zoe Mariño.;Ryosuke Tateishi.;Tatsuya Minami.;Angelo Sangiovanni.;Xavier Forns.;Hidenori Toyoda.;Stefano Brillanti.;Fabio Conti.;Elisabetta Degasperi.;Ming-Lung Yu.;Pei-Chien Tsai.;Kevin Jean.;Mohamed El Kassas.;Hend Ibrahim Shousha.;Ashraf Omar.;Claudio Zavaglia.;Hiroko Nagata.;Mina Nakagawa.;Yasuhiro Asahina.;Amit G Singal.;Caitlin Murphy.;Mohamed Kohla.;Chiara Masetti.;Jean-François Dufour.;Nicolas Merchante.;Luisa Cavalletto.;Liliana Lc Chemello.;Stanislas Pol.;Javier Crespo.;Jose Luis Calleja.;Rosanna Villani.;Gaetano Serviddio.;Alberto Zanetto.;Sarah Shalaby.;Francesco Paolo Russo.;Rob Bielen.;Franco Trevisani.;Calogero Cammà.;Jordi Bruix.;Giuseppe Cabibbo.;Maria Reig.
来源: Gut. 2022年71卷3期593-604页
The benefit of direct-acting antivirals (DAAs) against HCV following successful treatment of hepatocellular carcinoma (HCC) remains controversial. This meta-analysis of individual patient data assessed HCC recurrence risk following DAA administration.
1200. Utility of mismatch repair protein expression screening via an endoscopic ultrasound assessment of treatment-naive pancreas ductal adenocarcinoma.
作者: Ana Garcia Garcia de Paredes.;Rondell P Graham.;Michael J Levy.;Robert R McWilliams.;Elizabeth Rajan.;Lizhi Zhang.;Ferga C Gleeson.
来源: Gut. 2022年71卷1期219-221页 |